News

Exciting ESMO 2025 Highlights: Advanced Therapies from Akeso

Exciting ESMO 2025 Highlights: Advanced Therapies from Akeso

Exciting ESMO 2025 Highlights from Akeso

Akeso Inc. (9926.HK) is thrilled to share significant advancements in cancer treatment as they prepare for the upcoming 2025 European Society for Medical Oncology (ESMO) Annual Congress. An important part of this event will be the Late-Breaking Abstract (LBA) featuring results from the Phase III clinical study of ivonescimab—a first-in-class bispecific antibody that targets PD-1 and VEGF. This study will showcase the treatment of advanced squamous non-small cell lung cancer (sq-NSCLC) in a comparison against tislelizumab, another established therapy.

Key Presentation on Ivonescimab

The HARMONi-6 trial, led by the esteemed Professor Lu Shun from Shanghai Chest Hospital, will highlight compelling findings about ivonescimab in combination with chemotherapy. This study’s inclusion in the prestigious Presidential Symposium at ESMO reflects its significance in the scientific community. Presenting on a prestigious stage like this underscores the study's importance in paving the way for future treatment options in oncology.

What to Expect from the HARMONi-6 Study

During the presentation, attendees can anticipate in-depth insights into the efficacy and safety of ivonescimab. Data from this study will detail how the combination therapy improves patient outcomes, especially in maximizing progression-free survival (PFS). Importantly, these outcomes demonstrate ivonescimab’s transformative potential over first-generation immuno-oncology treatments, marking it as a pivotal step forward in cancer care.

Cadonilimab's Role in Advanced Gastric Cancer

In addition to ivonescimab, Akeso will also present results from the Phase III COMPASSION-15 clinical trial, which evaluates cadonilimab—another groundbreaking bispecific antibody targeting PD-1 and CTLA-4. Professor Shen Lin from Peking University Cancer Hospital will share the compelling data from this study on the treatment of unresectable gastric cancer. This presentation will be part of a Mini Oral Session at ESMO.

Impact of Cadonilimab in Clinical Practice

The COMPASSION-15 study's findings will reinforce cadonilimab's status as a transformative option in treating advanced gastric adenocarcinoma. With successful approval by regulatory agencies earlier this year, the drug's emerging data reflects its promising capabilities and the changing landscape of gastric cancer treatment. The inclusion of cadonilimab in the 2025 CSCO Gastric Cancer Guidelines further cements its position as a leading therapy and paves the way for better outcomes for patients worldwide.

Looking Forward: Akeso's Vision

Akeso's focus extends beyond these specific studies. The company is clearly dedicated to expanding their innovative pipeline. As they explore therapies for various disease states, their commitment to bridging the gap between traditional and novel treatment strategies remains a priority. This includes advancing treatment methodologies that not only improve health outcomes but also provide accessible medicine globally.

Frequently Asked Questions

What are the highlights of Akeso's presentations at ESMO 2025?

Akeso will showcase pivotal findings from the HARMONi-6 study on ivonescimab and the COMPASSION-15 trial on cadonilimab, indicating promising advancements in cancer treatment.

What is ivonescimab, and why is it significant?

Ivonescimab is a novel bispecific antibody targeting PD-1 and VEGF, promising to improve treatment strategies for advanced sq-NSCLC compared to existing therapies.

Who will present the studies at the conference?

Professor Lu Shun will present the HARMONi-6 results, while Professor Shen Lin will discuss findings from the COMPASSION-15 trial.

How does cadonilimab compare to other treatments?

Cadonilimab has shown transformative potential in treating advanced gastric cancer, outperforming many existing therapies and is recognized in national guidelines.

What is Akeso's overarching goal in cancer treatment?

Akeso aims to develop first-in-class therapies and enhance treatment efficacy across various cancers while ensuring global access to innovative medicines.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 152

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 120

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
IIT Madras Maps 100 Brains in a Serious Science Bet

Updated Category News Views 14

A human brain turned into a navigable cellular map is not a flashy launch-day trinket. It is painstaking infrastructure, the kind that can sit quietly for years before researchers figure out what it truly unlocks. That is why the Sudha Gopalakrishnan Brain Centre mission at IIT Madras deserves a serious look rather than the usual chest-thumping over a big scientific...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 127

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 249

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 184

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading

Top 5 Most Recently Viewed Articles

Kos Biotechnology Closes Record-Breaking $123M Fund

Updated Category News Views 80

Unprecedented Funding for Life Sciences When you hear about a $123 million fund popping up from nowhere, you stop and take notice. Kos Biotechnology Partners, a name that's bursting onto the scene with a hefty global life sciences fund, isn't messing around. Got their roots sinking into both New York and the ancient soil of Athens—this isn't just some flash-in-the-pan...

Continue Reading
Lyric Advances Battery Technology with Innovative Equipment

Updated Category News Views 149

Lyric's Innovative Contributions in Battery Technology Recently, Lyric successfully shipped its first solid-state battery front-end equipment to a customer, marking a significant milestone in their ongoing advancements in battery production technology. This achievement is a testament to Lyric's extensive experience and deep expertise in the field of solid-state batteries,...

Continue Reading
Danish Stock Market Update: Modest Decline and Notable Movers

Updated Category News Views 226

Danish Stock Market Sees Modest Decline The recent trading session in Denmark concluded with a slight downturn, marking a challenging day for investors as the OMX Copenhagen 20 index closed lower. The end of trading saw the index experiencing a reduction of 0.23%, setting a new six-month low. Such fluctuations can often reflect broader economic sentiments and provide...

Continue Reading
LiTHOS Group Advances Lithium Extraction with New Patent

Updated Category News Views 275

LiTHOS Group Innovates Lithium Extraction Techniques LiTHOS Group Ltd. (CBOE CA: LITS), a leader in sustainable lithium brine extraction, has achieved a significant milestone by securing a U.S. patent. The United States Patent and Trademark Office (USPTO) has allowed their patent for the "Electro-Pressure Membrane Method for Recovery and Concentration of Lithium from...

Continue Reading
Karbach Brewing: Your Ideal Venue for Memorable Celebrations

Updated Category News Views 378

Karbach Brewing: A New Venue for Unforgettable Corporate Events As the festive season approaches, businesses in Houston are searching for the ideal place to host their corporate holiday celebrations. Enter Karbach Brewing, a name that is rapidly becoming synonymous with memorable experiences. This brewery is not just about beer; it offers companies a distinctive setting...

Continue Reading